RECURRENT MALIGNANT GLIOMA
Clinical trials for RECURRENT MALIGNANT GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on recurrent brain tumors in early trial
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy called anti-GARP CAR T-cell therapy for people with recurrent high-grade gliomas (aggressive brain tumors). Researchers will take a patient's own immune cells, modify them in the lab to target a protein called GARP fou…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Promising targeted therapy for tough brain cancers moves forward
Disease control Recruiting nowThis study is testing a drug called Lutathera in children and young adults (ages 4 to 39) whose brain tumors have come back or are growing despite treatment. The drug delivers radiation directly to tumor cells that show up on a special PET scan. The goal is to find the safest dos…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cold virus hijacked to attack returning brain tumors in early trial
Disease control Recruiting nowThis early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC